Search research articles
Contact Us
Filters
Showing results (31-40 of 34) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 34 results.
The American Journal of Cardiology
|
May 19, 2020
Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography
Martin Robert Grübler, Graciela Delgado, Marcus Kleber, et al.
Clinical Chemistry and Laboratory Medicine
|
April 23, 2017
Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial
Nicolas Verheyen, Andreas Meinitzer, Martin Robert Grübler, et al.
Science (New York, N.Y.)
|
March 24, 2007
Multiple high-throughput analyses monitor the response of E. coli to perturbations
Nobuyoshi Ishii, Kenji Nakahigashi, Tomoya Baba, et al.
Human Vaccines & Immunotherapeutics
|
October 18, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
Brandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 34) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 34 results.
The American Journal of Cardiology
|
May 19, 2020
Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography
Martin Robert Grübler, Graciela Delgado, Marcus Kleber, et al.
Clinical Chemistry and Laboratory Medicine
|
April 23, 2017
Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial
Nicolas Verheyen, Andreas Meinitzer, Martin Robert Grübler, et al.
Science (New York, N.Y.)
|
March 24, 2007
Multiple high-throughput analyses monitor the response of E. coli to perturbations
Nobuyoshi Ishii, Kenji Nakahigashi, Tomoya Baba, et al.
Human Vaccines & Immunotherapeutics
|
October 18, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
Brandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, et al.
Page
of 4